Market Updates, Products & Ingredients

GC Rieber VivoMega Plans to Continue Expansion of Omega-3 Capacity

Most recently, the company finished constructing a 24,000 metric ton tank park in 2020 as part of ongoing efforts to meet demand.

...

By: Mike Montemarano

GC Rieber VivoMega, a global omega-3 concentrates supplier, has announced its plans to continue to develop its facilities and tanks for increased ingredient capacity over the next few years. This follows the most recent expansion the company made in 2020, when it finished constructing a 24,000 metric ton tank park, with the ongoing goal of withstanding current supply chain challenges faced by the whole industry, and continuing steady output that can meet future demand in the years ahead.
 
Across its history, GC Rieber first constructed a fish oil concentrate factory in Norway, and in both 2013 and 2016, the company completed two more expansions to its factory to meet market demands.
 
Then, in 2018 and 2019, the company took its expansion plans a step further with larger facilities, and updated technology. These upgrades enabled the launch of the company’s platinum range of VivoMega concentrates, with its highest-ever potency of 800 mg/g minimum EPA and DHA content. These updates were in order to help GC Rieber VivoMega to attain a supply with low oxidation, and to minimize the chance of a fishy aftertaste or burps.
 
“Everything we have accomplished so far with our facility expansions and upgrades is part of a bigger plan we have developed to help GC Rieber VivoMega to be able to become the leading supplier of high purity, high potency omega-3 concentrates across the globe,” said Ståle Søfting, sales and marketing director of GC Rieber VivoMega, said. “2019’s expansion was step five of our plan and we have been working hard the last two years to prepare for step six. We look forward to revealing what’s next in 2022.”
 
Since 2015, VivoMega has achieved lower oxidation values than global standards, the company reports, which include 75% lower oxidation than IFOS’s 5 star rating, and 80% lower than the GOED monograph.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Related Breaking News